Zeno Földes-Papp

Prof. Dr. Zeno Földes-Papp

Geatrics, Asklepsios, Lindau, Bavaria, Germany
orcid
Prof. Dr.med. Dr.rer.nat. Zeno Földes-Papp is in his retirem...

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 1986 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BSB Sarkadi
B Sarkadi
AEAgnes Enyedi
Agnes Enyedi
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
GGG Gárdos
G Gárdos
In inside-out red cell membrane vesicles active calcium transport and the formation of the enzyme-phosphate complex (EP) of the calcium pump were simultaneously investigated and the effects of a limited proteolytic digestion examined. In order to visualize the proteolyzed EP forms we have induced the formation of a maximum level EP from [.gamma.-32P]ATP in the presence of Ca2+ + La3+ and applied a good-resolution acidic discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis system. Proteolysis of inside-out vesicle membranes by trypsin, Pronase, papain, or chymotrypsin produces a calmodulin-like activation of the calcium pump, abolishes its calmodulin sensitivity, and decreases the original 140-kDa EP complex to a limit polypeptide of 80 kDa. Trypsin digestion produces another major intermediary fragment of 90 kDa, which is still a low-activity calmodulin-sensitive form of the pump. The red cell calcium pump is activated by trypsin both in the absence and presence of Ca2+ during digestion although the rate of activation and the appearance of the 80-kDa polypeptide are enhanced by Ca2+. If proteolytic digestion is carried out by chymotrypsin a calmodulin-insensitive maximum activation of the calcium pump coincides with the formation of a 125-130-kDa EP-forming polypeptide. Chymotrypsin and carboxypeptidase A have synergistic effects on the formation of this latter high-activity species. Based on these data we suggest a probable molecular arrangement for the functional parts of the red cell membrane calcium pump.

1 August 1998 in Journal of Biotechnology
Verified
Journal Article
Closed access
RRRudolf Rigler
Rudolf Rigler
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
FMFranz-Josef Meyer-Almes
Franz-Josef Meyer-Almes
CSCyra Sammet
Cyra Sammet
MVMartin Völcker
Martin Völcker
ASAndreas Schnetz
Andreas Schnetz

1 August 2010 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
RPRobert F. Place
Robert F. Place
ENEmily J. Noonan
Emily J. Noonan
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
LLLong-Cheng Li
Long-Cheng Li
RNA interference (RNAi) is an evolutionary conserved mechanism by which small double-stranded RNA (dsRNA) — termed small interfering RNA (siRNA) — inhibit translation or degrade complementary mRNA sequences. Identifying features and enzymatic components of the RNAi pathway have led to the design of highly-effective siRNA molecules for laboratory and therapeutic application. RNA activation (RNAa) is a newly discovered mechanism of gene induction also triggered by dsRNAs termed small activating RNA (saRNA). It offers similar benefits as RNA interference (RNAi), while representing a new method of gene overexpression. In the present study, we identify features of RNAa and explore chemical modifications to saRNAs that improve the applicability of RNAa. We evaluate the rate of RNAa activity in order to define an optimal window of gene induction, while comparing the kinetic differences between RNAa and RNAi. We identify Ago2 as a conserved enzymatic component of both RNAa and RNAi implicating that saRNA may tolerate modification based on Ago2 function. As such, we define chemical modifications to saRNAs that manipulate RNAa activity, as well as exploit their effects to design saRNAs with enhanced medicinal properties. These findings reveal functional features of RNAa that may be utilized to augment saRNA function for mechanistic studies or the development of RNAa-based drugs.

1 September 2009 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
KKKarsten Konig
Karsten Konig
HSHauke Studier
Hauke Studier
RBReiner Buckle
Reiner Buckle
HBH. Georg Breunig
H. Georg Breunig
GKGerhard M. Kostner
Gerhard M. Kostner
The binding of superquencher molecular beacon (SQMB) probes to human single-stranded cellular miRNA- 122 targets was detected in various single live cells with femtosecond laser microscopy. For delivery of the SQMBprobes, 3D-nanoprocessing of single cells with sub-15 femtosecond 85 MHz near-infrared laser pulses was applied. Transient nanopores were formed by focusing the laser beam for some milliseconds on the membrane of a single cell in order to import of SQMB-probes into the cells. In single cells of the human liver cell lines Huh-7D12 and IHH that expressed miRNA-122, we measured target binding in the cytoplasm by two-photon fluorescence imaging. We found increased fluorescence with time in a nonlinear manner up to the point where steady state saturation was reached. We also studied the intracellular distribution of target SQMB and provide for the first time strong experimental evidence that cytoplasmic miRNA travels into the cell nucleus. To interpret nonlinear binding, a number of individual miRNA-122 positive cells (Huh-7D12 and IHH) and negative control cells, human VA13 fibroblasts and Caco-2 cells were analyzed. Our experimental data are consistent with the cytoplasmic assembly of nuclear miRNA and provide further mechanistic insight in the regulatory function of miRNAs in cellular physiology. An open issue in the regulation of gene expression by miRNA is whether miRNA can activate gene expression in addition to the well-known inhibitory effect. A first step for such a regulatory role could be the travelling of miRNA-RISC into the nucleus.

1 April 2001 in Journal of Biotechnology
Verified
Journal Article
Closed access
MSMarkus Sauer
Markus Sauer
BAB. Angerer
B. Angerer
WAW. Ankenbauer
W. Ankenbauer
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
FGF. Göbel
F. Göbel
CZC. Zander
C. Zander

1 December 2003 in International Immunopharmacology
Verified
Journal Article
Closed access
Zeno Földes-PappZeno Földes-Papp
Zeno Földes-Papp
UDUlrike Demel
Ulrike Demel
GTGernot P. Tilz
Gernot P. Tilz